Overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) has been implicated as a potential mechanism of stroke and has been shown to damage various cellular components, including proteins, lipids, and DNA. Free-radicals, particularly superoxide (O2-), and non-radicals, such as hydrogen peroxide (H2O2), can be produced in large quantities and participate in the secondary injury process of ischemia. Free-radical scavengers have been extensively studied to reduce ROS/RNS burden and subsequent oxidative stress in cells. Although the overall goal is to counteract the deleterious effects of ROS/RNS in stroke pathology, success has been limited, especially in human clinical trials.
Fig. 1. Effect of treatment with disodium NXY-059 within 6hours after the onset of ischemic stroke on the primary outcome. (Wang et al., 2007)
Ace Therapeutics is a leading preclinical CRO in the field of stroke, providing reliable free-radical scavenger/antioxidant development services. Our dedicated team of scientists combines their expertise in molecular biology, medicinal chemistry, and neurobiology to help clients develop free-radical scavengers and antioxidants that can counteract the deleterious effects of ROS/RNS in stroke.
From early discovery to safety assessment, we have the tools and experience to cost-effectively develop free-radical scavengers and antioxidants. Achieve more definitive proof-of-concept and robust screening with our validated stroke models, and optimize study model design and management with the help of our team.
Our high-throughput screening platform efficiently and accurately identifies and determines molecules with the potential to scavenge free-radicals and mitigate oxidative stress. Using advanced algorithms and simulations, we can predict the binding affinity and selectivity of potential compounds to guide the design and optimization of potent free-radical scavengers and antioxidants.
We leverage our expertise to modify the chemical structure of free-radical scavengers and antioxidants to improve their bioavailability, stability, and target specificity. In addition, we offer drug delivery system development services to deliver free-radical scavengers/antioxidants to the brain.
Our team combines stroke-related expertise with extensive knowledge of molecules, modalities, and stroke model systems to create a mature portfolio of in vitro and in vivo stroke models to support pharmacological studies of free-radical scavengers/antioxidants and deepen your understanding of new stroke therapies. In addition, we provide safety assessment of free-radical scavengers/antioxidants on the central system and DMPK studies.
At Ace Therapeutics, we pride ourselves on our commitment to excellence and innovation in stroke drug development. We are your trusted partner for comprehensive services in the development of free-radical scavengers/antioxidants for the treatment of stroke. If you are interested in our services, please do not hesitate to contact us!
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.